Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report

Autor: Lauma Vasilevska, Madara Auzenbaha, Ieva Grinfelde, Anita Skangale

Publikováno v: Frontiers in Pediatrics, Vol 10 (2022)

Mucopolysaccharidosis type I S (MPS IS) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the IDUA gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Enzyme replacement therapy (ERT) reduces lysosomal stora

Externí odkaz: https://doaj.org/article/cf38c9f31df4419b8f4997af663ca955

Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection

Autor: Szu-Hsuan Chen, Irene Wang, Han-Lin Hsu, Chi-Ching Huang, Yi-Jun Liu, Denise Utami Putri, Chih-Hsin Lee

Publikováno v: Journal of Infection and Public Health, Vol 13, Iss 9, Pp 1354-1359 (2020)

Background: Treatment of latent tuberculosis infection (LTBI) is an important strategy for active disease prevention. Conventional in-person DOT (CDOT) programs are challenged by patient dissatisfaction over problems of convenience and privacy. The p

Externí odkaz: https://doaj.org/article/c8b63ab47108405493a746f4d530203a

An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study

Autor: Tom A Yates, Molebogeng X Rangaka, Marie Francis, Andre Charlett, Peter J White, V. Hack, Lara Goscé, Helen R. Stagg, Heinke Kunst, Laura Muñoz, Ibrahim Abubakar, Julian Surey, Marc Lipman

Publikováno v: BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Surey, J, Stagg, H R, Yates, T A, Lipman, M, White, P J, Charlett, A, Muñoz, L, Goscé, L, Rangaka, M X, Francis, M, Hack, V, Kunst, H & Abubakar, I 2021, ' An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England : the HALT LTBI pilot study ', BMC Infectious Diseases, vol. 21, 90 . https://doi.org/10.1186/s12879-021-05766-9
BMC INFECTIOUS DISEASES
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
BMC Infectious Diseases

Background Ending the global tuberculosis (TB) epidemic requires a focus on treating individuals with latent TB infection (LTBI) to prevent future cases. Promising trials of shorter regimens have shown them to be effective as preventative TB treatmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9141b0d81dc7dee4f14b991a27af852c
https://doaj.org/article/5e13b92cf17f4c9e8cd34ec43509a8b1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.